BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 29374487)

  • 1. Current trials for frontline therapy of mantle cell lymphoma.
    Steiner RE; Romaguera J; Wang M
    J Hematol Oncol; 2018 Jan; 11(1):13. PubMed ID: 29374487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
    Nabrinsky E; Danilov AV; Koller PB
    Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
    Nastoupil LJ; Koff JL; Flowers CR
    Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
    Klener P
    Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
    Kahl BS; Dreyling M; Gordon LI; Quintanilla-Martinez L; Sotomayor EM
    Leuk Lymphoma; 2017 Jul; 58(7):1561-1569. PubMed ID: 28140709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle cell lymphoma: evolving management strategies.
    Campo E; Rule S
    Blood; 2015 Jan; 125(1):48-55. PubMed ID: 25499451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of mantle cell lymphoma in the primary setting.
    Tang C; Kuruvilla J
    Expert Rev Hematol; 2019 Sep; 12(9):715-721. PubMed ID: 31268728
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma.
    Munger CM; Hegde GV; Weisenburger DD; Vose JM; Joshi SS
    Cancer Immunol Immunother; 2012 Oct; 61(10):1819-32. PubMed ID: 22441656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-chemotherapy Options for Newly Diagnosed Mantle Cell Lymphoma.
    Takiar R; Phillips T
    Curr Treat Options Oncol; 2021 Sep; 22(11):98. PubMed ID: 34524546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
    Avivi I; Goy A
    Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
    Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
    Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mantle cell lymphoma: are current therapies changing the course of disease?
    Geisler C
    Curr Oncol Rep; 2009 Sep; 11(5):371-7. PubMed ID: 19679012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapies for mantle cell lymphoma: current challenges and a brighter future.
    Skarbnik AP; Smith MR
    Discov Med; 2013 Mar; 15(82):177-87. PubMed ID: 23545046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current overview and treatment of mantle cell lymphoma.
    Schieber M; Gordon LI; Karmali R
    F1000Res; 2018; 7():. PubMed ID: 30109020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
    Lenz G; Dreyling M; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.
    Klener P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.